UB Paderborn / Katalog / Suche / in CDI

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Circulation (New York, N.Y.), 2014-07, Vol.130 (2), p.138-146

2014

Link zum Volltext

Verfügbarkeit prüfen

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Circulation (New York, N.Y.), 2016-01, Vol.133 (4), p.352-360

2016

Link zum Volltext

Verfügbarkeit prüfen

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation

Circulation (New York, N.Y.), 2019-02, Vol.139 (6), p.787-798

2019

Link zum Volltext

Verfügbarkeit prüfen

Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial

Circulation (New York, N.Y.), 2010-06, Vol.121 (23), p.2575-2583

2010

Link zum Volltext

Verfügbarkeit prüfen

Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease

Circulation (New York, N.Y.), 2009-12, Vol.120 (23), p.2337-2344

2009

Link zum Volltext

Verfügbarkeit prüfen

Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery

Circulation (New York, N.Y.), 2001-01, Vol.103 (3), p.363-368

2001

Link zum Volltext

Verfügbarkeit prüfen

Response by Piccini et al to Letters Regarding Article, “Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation”

Circulation (New York, N.Y.), 2016-07, Vol.134 (2), p.e7-e8

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acute ischemic stroke. Part I: Recanalization strategies

Circulation (New York, N.Y.), 2002-09, Vol.106 (12), p.1563-1569

2002

Link zum Volltext

Verfügbarkeit prüfen

Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

Circulation (New York, N.Y.), 2013-09, Vol.128 (11)

2013

Link zum Volltext

Verfügbarkeit prüfen

Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

Circulation (New York, N.Y.), 2013-09, Vol.128 (11), p.e172-e173

2013

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acute ischemic stroke. Part II: Neuroprotection and medical management

Circulation (New York, N.Y.), 2002-09, Vol.106 (13), p.1736-1740

2002

Link zum Volltext

Verfügbarkeit prüfen

Response to Letter Regarding Article, “Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease”

Circulation (New York, N.Y.), 2010-07, Vol.122 (3)

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 15083: Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial

Circulation (New York, N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A15083-A15083

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation

Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease: Results From the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial

Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis

Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery

Response by Piccini et al to Letters Regarding Article, “Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation”

Treatment of acute ischemic stroke. Part I: Recanalization strategies

Treatment of acute ischemic stroke. Part II: Neuroprotection and medical management

Response to Letter Regarding Article, “Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease”

Abstract 15083: Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial

Aktive Filter

Suchergebnisse filtern